Arg1265
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg1265  -  DDX9 (human)

Site Information
TGYFGQGrGGGGY__   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9480274

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 )
Disease tissue studied:
colorectal cancer ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , colorectal carcinoma ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 )
Relevant cell line - cell type - tissue:
HCT116 (intestinal) ( 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , HeLa S3 (cervical) ( 2 ) , Jurkat (T lymphocyte) ( 3 )

References 

1

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

2

Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837   Curated Info

3

Uhlmann T, et al. (2012) A method for large-scale identification of protein arginine methylation. Mol Cell Proteomics 11, 1489-99
22865923   Curated Info

4

Mulhern D (2012) CST Curation Set: 13536; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

5

Possemato A (2010) CST Curation Set: 9390; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Possemato A (2010) CST Curation Set: 8850; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Possemato A (2010) CST Curation Set: 8858; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Possemato A (2010) CST Curation Set: 8855; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

Possemato A (2010) CST Curation Set: 8852; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

10

Possemato A (2010) CST Curation Set: 8851; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

11

Possemato A (2010) CST Curation Set: 8848; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

12

Possemato A (2010) CST Curation Set: 8857; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

13

Possemato A (2010) CST Curation Set: 8853; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

14

Possemato A (2010) CST Curation Set: 8847; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

15

Possemato A (2010) CST Curation Set: 8845; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

16

Possemato A (2010) CST Curation Set: 8856; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

17

Possemato A (2010) CST Curation Set: 8844; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

18

Zhou J (2009) CST Curation Set: 6946; Year: 2009; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info